Taylor & Francis Group
Browse
Supplementary figures and tables.docx (1.14 MB)

Supplementary figures and tables: Real-world Evidence Comparing Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Systematic Review and Network Meta-analysis.docx

Download (1.14 MB)
dataset
posted on 2022-04-01, 08:51 authored by Steven Deitelzweig, Evelien Bergrath, Manuela Di Fusco, Amiee Kang, Mirko Savone, Joseph C Cappelleri, Cristina Russ, Marissa Betts, Allie Cichewicz, Kassandra Schaible, Jialu Tarpey, Kyle Fahrbach

Supplementary Figure 1. Real-world Evidence Comparing Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Systematic Review and Network Meta-analysis

‘Risk of Bias Assessment Results by Outcome for Studies Included in Base-case Analysis Using Risk of Bias in Non-randomized Studies of Interventions’

Supplementary Figure 2. Real-world Evidence Comparing Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Systematic Review and Network Meta-analysis

‘Risk of Bias Assessment Results by Domain for Studies Included in Base-case Analysis Using Risk of Bias in Non-randomized Studies of Interventions’

Supplementary Figure 3. Real-world Evidence Comparing Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Systematic Review and Network Meta-analysis

‘Network Meta-analysis Results for Ischemic Stroke’

Supplementary Figure 4. Real-world Evidence Comparing Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Systematic Review and Network Meta-analysis

Network Meta-analysis Results for Intracranial Hemorrhage’

Supplementary Figure 5. Real-world Evidence Comparing Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Systematic Review and Network Meta-analysis

‘Network Meta-analysis Results for Gastrointestinal Bleeding’


Supplementary Figure 6. Real-world Evidence Comparing Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Systematic Review and Network Meta-analysis

‘Network Meta-analysis Results for All-cause Mortality’

Supplementary Table 1. Real-world Evidence Comparing Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Systematic Review and Network Meta-analysis

Search Strategy’

Supplementary Table 2. Real-world Evidence Comparing Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Systematic Review and Network Meta-analysis

‘Population, Interventions and Comparisons, Outcomes, Study Design, and Time Period Selection Criteria’

Supplementary Table 3. Real-world Evidence Comparing Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Systematic Review and Network Meta-analysis

‘Process for Selecting Data among Kin Publications’

Supplementary Table 4. Real-world Evidence Comparing Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Systematic Review and Network Meta-analysis

‘Key Characteristics from Studies Included in the Network Meta-analysis’

Supplementary Table 5. Real-world Evidence Comparing Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Systematic Review and Network Meta-analysis

Outcomes from Studies Included in the Network Meta-analysis’

PRISMA checklist. Real-world Evidence Comparing Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Systematic Review and Network Meta-analysis

‘PRISMA 2020 Checklist’

Funding

Bristol-Myers Squibb

Pfizer

History